Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2004

View Archived Issues

OATs mediate muscular side effects of HMG-CoA reductase inhibitors

Novel NNRTIs for HIV

ProtoKinetix obtains option to license mammastatin-based products

CellTech and Biogen Idec enter CD40L collaboration for autoimmune disease

GeneProt amends collaboration with Novartis

Strong antiretroviral response found with fosamprenavir in naive HIV-infected patients

Improved efficacy of antianginal drugs after coadministration with ranolazine

Preliminary results of adalimumab in the treatment of chronic plaque psoriasis

Connetics to acquire Soriatane

Eisai licenses rufinamide from Novartis

Transgene updates status of phase II trials of MVA-Muc1-IL2

NexMed enters agreement to develop topical pain relief gel

Nabi signs distribution agreement with Kamada for Nabi-HB

Matrixx reaffirms safety of Zicam intranasal gel

Genome Therapeutics completes merger with Genesoft

Neurocrine Biosciences updates clinical programs

Clinical benefits of topical tacrolimus in the treatment of skin disorders

2003 reportedly an important year of transition at InterMune

PharmaMar refocuses business plan

Mechanistic basis for novel therapeutic strategies aimed at reducing BH4 levels in ischemic stroke

Yamanouchi presents new inhibitors of reverse Na+/Ca2+ exchange

Novel HIV reverse transcriptase inhibitors claimed by BMS team

Euroceltique patent covers new inhibitors of VR1 and/or mGluR receptors

German scientists present proapoptotic IAP modulators for use in cancer therapy

Two series of antibacterial macrolides presented by Enanta researchers

AstraZeneca describes three series of cathepsin S inhibitors

New glucokinase activators in early development at Novo Nordisk

Potential utility of Tamiflu for avian flu

New study evaluates GTI-2040 plus gemcitabine for solid tumors

Launch of Climara Pro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...